Prosecution Insights
Last updated: October 02, 2026
Application No. 18/222,313

IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES

Non-Final OA §102
Filed
Jul 14, 2023
Priority
Jan 15, 2021 — provisional 63/138,360 +2 more
Examiner
PUTTLITZ, KARL J
Art Unit
1646
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Seagen Inc.
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
990 granted / 1432 resolved
+9.1% vs TC avg
Strong +19% interview lift
Without
With
+18.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
62 currently pending
Career history
1487
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
36.6%
-3.4% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
28.3%
-11.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1432 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election in the reply filed on 7/30/2026 is acknowledged: PNG media_image1.png 168 676 media_image1.png Greyscale PNG media_image2.png 260 564 media_image2.png Greyscale Claims 1, 36 and 105 cover the elected invention and are treated on the merits, below. Claims 69, 85, 91, 106, 107, 113, 117, 118, 153, 186, 193, 209-211, 216, 303, 332-333, 338, 352, 360, 365, 377-378, 508-511, and 516-522 are withdrawn from consideration as exclusively covering a non-elected invention and species. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 and 36 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by WO 2021202984 (WO 984). WO 984 teaches linker-payload compounds that anticipate the rejected claims within the meaning of section 102. See, for example, the following compounds at page 116: PNG media_image3.png 134 478 media_image3.png Greyscale PNG media_image4.png 454 452 media_image4.png Greyscale Claim 105 is objected to for dependance on one or more rejected claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KARL J PUTTLITZ whose telephone number is (571)272-0645. The examiner can normally be reached on Monday to Friday from 9 a.m. to 5 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gregory Emch, can be reached at telephone number 571-272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KARL J PUTTLITZ/ Primary Examiner, Art Unit 1646
Read full office action

Prosecution Timeline

Jul 14, 2023
Application Filed
Aug 20, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741039
Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical
4y 4m to grant Granted Sep 22, 2026
Patent 12734244
ANTIBODY-DRUG CONJUGATES AND THEIR USES
2y 0m to grant Granted Sep 15, 2026
Patent 12723130
DIOL COMPOSITION AND POLYESTER
6y 3m to grant Granted Sep 01, 2026
Patent 12721906
KIDNEY TARGETED DELIVERY OF DRUGS
3y 4m to grant Granted Sep 01, 2026
Patent 12721893
Antigen-Binding Protein Targeting CD70 and Use Thereof
3y 3m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
88%
With Interview (+18.6%)
2y 6m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1432 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month